Vasopharm GmbH
Records under this name other than the patents Vasopharm GmbH holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 2 patents it holds.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,016,431 | Solid Pharmaceutical Compositions Comprising Biopterin Derivatives and Uses of Such Compositions Formerly held In force · High confidence | In force | High confidence | |
| US 10,493,075 | Solid Pharmaceutical Compositions Comprising Biopterin Derivatives and Uses of Such Compositions Formerly held In force · High confidence | In force | High confidence | |
| US 10,925,877 | Solid Pharmaceutical Compositions Comprising Biopterin Derivatives and Uses of Such Compositions Formerly held In force · High confidence | In force | High confidence | |
| US 9,895,372 | Solid Pharmaceutical Compositions Comprising Biopterin Derivatives and Uses of Such Compositions Formerly held In force · High confidence | In force | High confidence | |
| US 12,171,766 | Methods of Treating Patients Suffering from Brain Injury and Methods of Increasing the Value of the Extended Glasgow Outcome Scale of Patients Suffering from Brain Injury Formerly held In force · High confidence | In force | High confidence | |
| US 8,222,238 | Use of pteridine derivatives for the treatment of increased intracranial pressure, secondary ischemia, and disorders associated with an increased level of cytotoxic reactive oxygen species Term ended Term ended Apr 22, 2024 · From the USPTO record | Term ended | Term ended Apr 22, 2024 | From the USPTO record |
| US 7,541,360 | 4-amino-7,8-dihydropteridines, pharmaceutical compositions containing them and their use for the treatment of diseases which are caused by an increased nitric oxide level Term ended Term ended Dec 30, 2023 · From the USPTO record | Term ended | Term ended Dec 30, 2023 | From the USPTO record |
| US 9,382,252 | Use of pteridine derivatives for the treatment of increased intracranial pressure, secondary ischemia, and disorders associated with an increased level of cytotoxic reactive oxygen species Term ended Term ended Oct 8, 2023 · From the USPTO record | Term ended | Term ended Oct 8, 2023 | From the USPTO record |
| US 9,422,289 | Use of pteridine derivatives for the treatment of increased intracranial pressure, secondary ischemia, and disorders associated with an increased level of cytotoxic reactive oxygen species Term ended Term ended Oct 8, 2023 · From the USPTO record | Term ended | Term ended Oct 8, 2023 | From the USPTO record |
| US 8,236,809 | Substituted 1,2,3-triazolopyrimidines for the inhibition of NAD(P)H oxidases and platelet activation Lapsed on the fee record Ended Aug 7, 2016 · From the USPTO record | Lapsed on the fee record | Ended Aug 7, 2016 | From the USPTO record |